Technical Analysis for NVUS - Novus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 1.63 -8.43% -0.15
NVUS closed down 8.43 percent on Friday, May 24, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical NVUS trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup -8.43%
Reversal New Lows Setup Bearish Swing Setup -8.43%
Wide Bands Range Expansion -8.43%
Oversold Stochastic Weakness -8.43%
Volume Surge Other -14.21%
Wide Bands Range Expansion -14.21%
Oversold Stochastic Weakness -14.21%

Older signals for NVUS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
Medicine Pharmaceutical Otorhinolaryngology Ear Pediatrics
Is NVUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.61
52 Week Low 1.52
Average Volume 59,371
200-Day Moving Average 3.7489
50-Day Moving Average 3.3188
20-Day Moving Average 2.3125
10-Day Moving Average 1.9939
Average True Range 0.283
ADX 57.84
+DI 7.2905
-DI 30.8813
Chandelier Exit (Long, 3 ATRs ) 2.241
Chandelier Exit (Short, 3 ATRs ) 2.479
Upper Bollinger Band 3.0346
Lower Bollinger Band 1.5904
Percent B (%b) 0.03
BandWidth 62.451892
MACD Line -0.4502
MACD Signal Line -0.4345
MACD Histogram -0.0157
Fundamentals Value
Market Cap 11.32 Million
Num Shares 6.94 Million
EPS -3.46
Price-to-Earnings (P/E) Ratio -0.47
Price-to-Sales 0.00
Price-to-Book 1.14
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.95
Resistance 3 (R3) 1.98 1.91 1.89
Resistance 2 (R2) 1.91 1.83 1.89 1.87
Resistance 1 (R1) 1.77 1.78 1.74 1.74 1.86
Pivot Point 1.70 1.70 1.68 1.68 1.70
Support 1 (S1) 1.56 1.62 1.53 1.53 1.40
Support 2 (S2) 1.49 1.57 1.47 1.39
Support 3 (S3) 1.35 1.49 1.37
Support 4 (S4) 1.32